News
FLGT
21.71
+0.09%
0.02
Fulgent Genetics: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 13h ago
Weekly Report: what happened at FLGT last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at FLGT last week (0311-0315)?
Weekly Report · 03/18 10:48
Weekly Report: what happened at FLGT last week (0304-0308)?
Weekly Report · 03/11 10:46
Fulgent Genetics: Correspondence
Press release · 03/08 16:05
Fulgent Genetics Price Target Cut to $25.00/Share From $28.00 by Piper Sandler
Dow Jones · 03/06 14:42
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Dow Jones · 03/06 14:42
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Benzinga · 03/06 14:31
Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)
TipRanks · 03/06 12:36
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Arrivent Biopharma, Ferguson and Target among companies with revised targets. Ferguson, Target and Box are among the companies with new analyst coverage. Analysts raised their ratings on Arrivent, Ferguson, and Target.
Reuters · 03/06 06:47
Weekly Report: what happened at FLGT last week (0226-0301)?
Weekly Report · 03/04 10:48
Fulgent Genetics Shares Business Insights in Investor Update
TipRanks · 02/28 12:22
Fulgent Genetics Non-GAAP EPS of $0.28 beats by $0.57, revenue of $70.51M beats by $4.19M
Fulgent Genetics reports Q4 non-GAAP EPS of $0.28, revenue of $70.51M beats by $4.19M. Core revenue grew 21% year-over-year to $66.5 million. Shares +5.85% in after-hours trading.
Seeking Alpha · 02/28 12:03
BRIEF-Fulgent Genetics Q4 Revenue USD 70.505 Million
Reuters · 02/28 12:00
*Fulgent Genetics 4Q Rev $70.5M >FLGT
Dow Jones · 02/28 12:00
*Fulgent Genetics 4Q Loss/Shr $4.30 >FLGT
Dow Jones · 02/28 12:00
*Fulgent Genetics 4Q Loss $128.1M >FLGT
Dow Jones · 02/28 12:00
Fulgent Genetics: Statement of changes in beneficial ownership of securities
Press release · 02/28 00:12
Fulgent Genetics Q4 2023 Earnings Preview
Fulgent Genetics (NASDAQ:FLGT) is scheduled to announce Q4 earnings results on Wednesday, February 28th. The consensus EPS Estimate is -$0.29 and the consensus revenue estimate is $66.32M. Over the last 2 years, FLGT has beaten earnings estimates 88% of the time.
Seeking Alpha · 02/27 18:22
Notable earnings before Wednesday's open
Seeking Alpha · 02/27 15:29
More
Webull provides a variety of real-time FLGT stock news. You can receive the latest news about Fulgent Genetics through multiple platforms. This information may help you make smarter investment decisions.
About FLGT
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.